Loading clinical trials...
Loading clinical trials...
Chamomile may possess anticoagulant effects based on the presence of coumarin-like compounds within the flower. This randomized complete crossover study will investigate the impact of chamomile ingestion acutely on coagulation.
Subjects will be enrolled into two groups in a crossover fashion upon obtaining written informed consent. The two intervention groups include (1) chamomile tea intake and (2) chamomile extract intake. Subjects will consume a single preparation of chamomile tea or extract capsule, and partake in a minimum of three days washout period between interventions. Screening assays of coagulation will be obtained immediately before the ingestion of chamomile, two hours after ingestion, and four hours after ingestion over the course of a single day.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
Yes
Stony Brook University Hospital
Stony Brook, New York, United States
Start Date
March 16, 2022
Primary Completion Date
May 12, 2022
Completion Date
May 12, 2022
Last Updated
June 10, 2022
8
ACTUAL participants
Chamomile Tea
DIETARY_SUPPLEMENT
Chamomile Extract Capsule
DIETARY_SUPPLEMENT
Lead Sponsor
Stony Brook University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00178594